Drug intelligence / Profile preview

ethinylestradiol + gestodene (Schering AG)

Development stage
Unknown
Lead developer
Deutsche Pharma
Modality
Small Molecules
Administration
Oral
01

Overview

Ginesse is a combined oral contraceptive containing the synthetic estrogen ethinylestradiol and the third-generation synthetic progestin gestodene. It is indicated for the prevention of pregnancy (contraception). Ethinylestradiol acts as an agonist of the estrogen receptors (ERα and ERβ), while gestodene acts as a potent agonist of the progesterone receptor (PR). Together, these hormones suppress the secretion of gonadotropins (luteinizing hormone and follicle-stimulating hormone) from the pituitary gland, thereby preventing ovulation, altering the cervical mucus to inhibit sperm penetration, and modifying the endometrium to prevent implantation. Ginesse is marketed by Deutsche Pharma in Chile.

Brand names
Ciclomex 20Ciclomex20Ciclomex-20Feminol 20Feminol20Feminol-20FemodeneGinesseGyneraHarmonetLindynetteLogestMelianeMelodeneMinesseMinuletMirelleTamisa 20/75
Other names
EE/GSDethinyl estradiol + gestodeneethinyloestradiol + gestodenegestodene + ethinyl estradiolgestodene + ethinylestradiolgestodene + ethinyloestradiol
02

Targets

PR (Progesterone receptor)GR (Glucocorticoid receptor)AR (Adrenergic receptors)ESR1 (ERα)MR (Mineralocorticoid receptor)

Beyond the preview

Go deeper on ethinylestradiol + gestodene (Schering AG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethinylestradiol + gestodene (Schering AG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call